Genix Pharmaceuticals Corporation
GENX.V
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.30K | -86.00K | -54.20K | -2.94M | -3.01M |
| Total Depreciation and Amortization | -- | 200.00 | 400.00 | 99.70K | 201.60K |
| Total Amortization of Deferred Charges | 800.00 | 600.00 | 400.00 | 1.00K | 800.00 |
| Total Other Non-Cash Items | -87.20K | -83.90K | -106.10K | 2.68M | 2.66M |
| Change in Net Operating Assets | 28.10K | 18.40K | 21.80K | 11.70K | -10.90K |
| Cash from Operations | -117.50K | -150.60K | -137.70K | -152.70K | -158.80K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 158.40K | 201.70K | 187.10K | 208.40K | 178.50K |
| Total Debt Repaid | -- | -- | -- | 5.00K | 5.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 113.90K | 146.40K | 137.60K | 157.10K | 135.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.60K | -4.20K | -100.00 | 4.40K | -23.20K |